MA12.08 Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma

Epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) are standard of care for non-small cell lung cancer (NSCLC) patients with EGFR-sensitive mutations. The histological transformation from NSCLC to small cell lung cancer (SCLC) is one of the mechanisms of resistance to EGFR-TKIs, and chemotherapy alone is usually administered to overcome such resistance. However, the prognosis after SCLC transformation is extremely poor. Therefore, we investigate whether chemotherapy in combination with TKIs or bevacizumab will improve efficacy.